The EARLY DELTA Trial

Thomas Ottens131 enrolled

Overview

Rationale: Delirium is a type of acute encephalopathy that is triggered by an underlying somatic disorder. Patients experience disturbances in attention, alertness and other cognitive functions. In patients with delirium, a characteristic electroencephalography (EEG) pattern is seen, known as polymorphic delta activity. The MDR certified medical device "Deltascan" can detect this EEG pattern. Traditional clinical delirium screening instruments are known to have limited sensitivity, in particular for detecting hypoactive delirium. We hypothesize that adding EEG based encephalopathy detection to clinical observation scales increases the sensitivity and results in earlier detection of delirium and subsyndromal delirium, resulting in improved clinical outcomes of critically ill patients, such as delirium duration, ICU length of stay or survival. Objective: This randomized controlled trial aims to study the effect of implementation of EEG based encephalopathy detection (DeltaScan, Prolira, Utrecht, The Netherlands, hereafter: DeltaScan) on relevant clinical endpoints (ICU length of stay, sedative requirements and delirium related complications, among others) in a mixed medical and surgical intensive care unit population. Study design: a randomized controlled trial Study population: adult patients (\>18 years) admitted to the ICU for unplanned care with a minimal anticipated ICU length of stay of 48h. Intervention: either usual care, where the patients' medical team obtains regular delirium screening, versus usual care plus twice daily DeltaScan measurements. During the daily medical rounds, the DeltaScan results will be presented to the patients' medical team together with decision support, consisting of DeltaScan trend interpretation and protocol-based suggestions for evaluation of underlying delirium cause. Main study parameters/endpoints: primary endpoint will be ICU length of stay. Secondary endpoints are encephalopathy/delirium occurrence, ICU encephalopathy/delirium free days, ventilator free days, organ support free days, sedative, opioid and antipsychotic drug requirement, delirium related complication occurrence, frequency and duration of physical restraints application, ICU mortality, ICU readmission, hospital length of stay, hospital mortality and 90-day mortality. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: In this study, it is not expected that randomization to the intervention group adds risk for patients. This is a study of a diagnostic intervention with additional encephalopathy/delirium observations consisting of a short (90 seconds) EEG measurement, which does not harm the patient. Clinicians will receive protocol-based decision support alongside the diagnostic observation. No additional medical treatments will be conducted as part of the study protocol.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult (18 years or above) admitted to ICU for any indication * ICU length of stay anticipated to be 48h or longer from time of screening for inclusion * Written informed consent by patient or representative Exclusion Criteria: * More than 48 hours have elapsed since the patient was first eligible to undergo a DeltaScan measurement after ICU admission. A patient is eligible for DeltaScan measurements if they are a. able to cooperate with simple instructions AND b. are alert or mildly sedated no deeper than a Richmond Agitation and Sedation Score of -2. * Admission for out-of-hospital cardiac arrest, status epilepticus, hemorrhagic or ischemic stroke, increased intracranial pressure, head trauma * Recent intracranial neurosurgery (\<30 days prior to inclusion) * Known space-occupying lesions in the brain or skull * Metal implants in brain or skull * Diagnosis of dementia or Parkinson's disease * Inpatient from nursing home * Lithium use (\<30 days prior to inclusion) * Imminent death or palliative care phase * Patients ánd their legal representatives both do not understand Dutch or English * Patients who participated in the EARLY DELTRA trial \<90 days ago

Outcomes

Primary Outcomes

ICU length of stay

Length of stay in the intensive care unit, measured in hours

Time frame: Assessed at the 90 day post discharge follow-up

Secondary Outcomes

Encephalopathy/delirium occurrence (DeltaScan)

Defined as: any DeltaScan score ≥ 3 OR initiation of antipsychotic treatment

Time frame: Assessed daily, until participant is discharged from ICU, or until the maximum observation time (30 days)

Delirium occurrence (ICDSC)

Defined as: any ICDSC score ≥ 4 OR initiation of antipsychotic treatment

Time frame: Assessed daily, until participant is discharged from ICU, or until the maximum observation time (30 days)

ICU encephalopathy/delirium and coma free days (reported as: composite, delirium free days, coma free days)

Defined as: the number of days in the first 14 days after the patient was randomized during which the patient was alive without delirium or coma. We will calculate this value separately based on DeltaScan alone, DeltaScan+ICDSC and ICDSC alone)

Time frame: Assessed at the 14th day after ICU admission. If the patient dies during the first 14 days of the study observation period, this outcome is assessed at the date of death

ICU ventilator free days

Defined as: the number of days in the first 14 days after the patient was randomized during which the patient was alive without mechanical ventilation, regardless of ventilation mode or route. High-flow nasal oxygen (HFNO) will not be regarded as ventilation. If patients are ventilated with a device provided by another institute (i.e. Centrum voor Thuisbeademing), only days spent on the ICU ventilator will be counted. Any day with \<12h of mechanical ventilation will be counted as 0,5 day. More than 12h of mechanical ventilation will be counted as 1 day

Time frame: Assessed at the 14th day after ICU admission. If the patient dies during the first 14 days of the study observation period, this outcome is assessed at the date of death

ICU organ support free days

Defined as: the number of days in the first 14 days after the patient was randomized during which the patient was alive without mechanical ventilation (any modality), HFNO, renal replacement therapy (any modality), mechanical circulatory support (ECLS, IABP, Impella), intravenous inotropes (dobutamine, milrinone, enoximone, levosimendan) or vasopressors (noradrenalin \> 0.25 mcg/kg/min or any dose of terlipressin / arginine vasopressin)

Time frame: Assessed at the 14th day after ICU admission. If the patient dies during the first 14 days of the study observation period, this outcome is assessed at the date of death

ICU mortality rate

Defined as death occurring before ICU discharge. Outcome reported as proportion of participants who died before ICU discharge.

Time frame: This is assessed at the date of death. In ICU survivors, it is assessed at the 90 day post-discharge follow-up

ICU readmission rate

Unplanned re-admission to the ICU before hospital discharge. Outcome reported as proportion of participants who were re-admitted to ICU before hospital discharge.

Time frame: This outcome is only scored when an unplanned re-admission occurs within the first 90 days after ICU discharge.

Hospital length-of-stay

Outcome reported in days

Time frame: Assessed at the 90 day post-discharge follow-up

Hospital mortality rate

Defined as death occurring before hospital discharge. Outcome reported as proportion of participants who died before hospital discharge.

Time frame: This is assessed at the date of death. In survivors, it is assessed at the 90 day post-discharge follow-up

90 day mortality rate

Defined as death occurring within 90 days after study enrollment. Outcome reported as proportion of participants who died before 90d follow-up

Time frame: Assessed at the 90 day post-discharge follow-up

ICU Sedative Drug requirement

The cumulative doses of the following sedative drugs, administered after randomisation: propofol, clonidine, dexmedetomidine, esketamine, zopiclone, benzodiazepines

Time frame: Assessed daily, until participant is discharged from ICU, or until the maximum observation time (30 days)

ICU opioid requirement

The cumulative doses of opioids, administered after randomisation

Time frame: Assessed daily, until participant is discharged from ICU, or until the maximum observation time (30 days)

ICU antipsychotic drug requirement

cumulative dose of the following antipsychotic drugs, administered after randomisation: haloperidol, quetiapine, other antipsychotic drugs

Time frame: Assessed at ICU Assessed daily, until participant is discharged from ICU, or until the maximum observation time (30 days)

ICU accidental device removal incidence and falls

Defined as the number of incidents where a patient accidentally removes an indwelling catheter, tube, infusion line or drain (e.g. intravenous lines, wound drains, airway device, feeding tubes etc) or falls out of bed

Time frame: Assessed daily, until participant is discharged from ICU, or until the maximum observation time (30 days)

ICU incidence and duration of the use of physical restraints

Defined as the frequency of application of physical restraints and the cumulative duration of restraint application during ICU admission

Time frame: Assessed daily, until participant is discharged from ICU, or until the maximum observation time (30 days)

Self-assessed quality of life

Self-assessed quality of life measured with the Euroqol Quality of Life questionnaire, version EQ6D

Time frame: Assessed one year after ICU discharge

Self assessed cognitive function

Self-assessed cognitive function measured with the cognitive failure questionnaire (CFQ, Merckelbach, Muris \& Nijman 1996)

Time frame: Assessed one year after ICU discharge

Self assessed mood and depression symptoms

Self assessed mood and depression symptoms measured with the Patient Health Questionnaire (PHQ-9)

Time frame: Assessed one year after ICU discharge

Self assessed mobility and physical functioning

Self assessed mobility and physical functioning measured with the Barthel Index

Time frame: Assessed one year after ICU discharge

The EARLY DELTA Trial

Overview

Conditions

Interventions

Eligibility

Locations (2)

Outcomes

Primary Outcomes

Secondary Outcomes